Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review

Daniel Pewsner, senior research fellow in general practice; and general practitioner,¹ Peter Jüni, reader in clinical epidemiology,² Matthias Egger, professor,³ Markus Battaglia, senior research fellow in general practice; and general practitioner,¹ Johan Sundström, associate professor,⁴ Lucas M Bachmann, reader in clinical epidemiology and deputy director⁵

¹Institute of Social and Preventive Medicine (ISPM), University of Bern, Finkenhubelweg 11, CH-3012 Bern, Switzerland; and Medix General Practice Network, Bern, Switzerland

²Institute of Social and Preventive Medicine (ISPM), University of Bern

³Institute of Social and Preventive Medicine (ISPM), University of Bern; and Department of Social Medicine, University of Bristol, Bristol

⁴Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden

⁵Horten Centre, University of Zurich, Zurich, Switzerland

Correspondence to: M Egger egger@ispm.unibe.ch

doi:10.1136/bmj.39276.636354.AE

ABSTRACT

Objective To review the accuracy of electrocardiography in screening for left ventricular hypertrophy in patients with hypertension.

Design Systematic review of studies of test accuracy of six electrocardiographic indexes: the Sokolow-Lyon index, Cornell voltage index, Cornell product index, Gubner index, and Romhilt-Estes scores with thresholds for a positive test of ≥ 4 points or ≥ 5 points.

Data sources Electronic databases ((Pre-)Medline, Embase), reference lists of relevant studies and previous reviews, and experts.

Study selection Two reviewers scrutinised abstracts and examined potentially eligible studies. Studies comparing the electrocardiographic index with echocardiography in hypertensive patients and reporting sufficient data were included.

Data extraction Data on study populations, echocardiographic criteria, and methodological quality of studies were extracted.

Data synthesis Negative likelihood ratios, which indicate to what extent the posterior odds of left ventricular hypertrophy is reduced by a negative test, were calculated.

Results 21 studies and data on 5608 patients were analysed. The median prevalence of left ventricular hypertrophy was 33% (interquartile range 23-41%) in primary care settings (10 studies) and 65% (37-81%) in secondary care settings (11 studies). The median negative likelihood ratio was similar across electrocardiographic indexes, ranging from 0.85 (range 0.34-1.03) for the Romhilt-Estes score (with threshold ≥ 4 points) to 0.91 (0.70-1.01) for the Gubner index. Using the Romhilt-Estes score in primary care, a negative electrocardiogram result would reduce the typical pre-test probability from 33% to 31%. In secondary care the typical pre-test probability of 65% would be reduced to 63%.

Conclusion Electrocardiographic criteria should not be used to rule out left ventricular hypertrophy in patients with hypertension.

INTRODUCTION

Arterial hypertension is a major cause of coronary heart disease, stroke, and heart failure. Several studies have shown that left ventricular hypertrophy is an important risk factor in patients with hypertension, leading to a fivefold to 10-fold increase in cardiovascular risk,¹⁻⁵ which is similar to the increase seen in patients with a history of myocardial infarction.⁶ The presence of left ventricular hypertrophy, in addition to hypertension, thus has important implications for assessing risk and managing patients, including decisions on interventions other than antihypertensive treatment, such as lipid lowering treatment and lifestyle modifications.^{7,8} Accurate and early diagnosis of left ventricular hypertrophy is therefore an important component of the care of patients with hypertension.

Decisions about treatment should be based on assessments of hypertensive target organ damage and overall cardiovascular risk. The appropriate diagnostic work-up of suspected left ventricular hypertrophy in patients with hypertension is less clear, however. More than 30 different electrocardiographic indexes for the diagnosis of left ventricular hypertrophy, based on the standard 12 lead electrocardiogram, have been described. Many of the proposed indexes have remained anecdotal, but others are commonly used, including the Sokolow-Lyon index,⁹ the Cornell voltage index,¹⁰ the Cornell product index,¹¹ the Gubner index,¹² and the Romhilt-Estes scores.¹³ However, debate about their comparative diagnostic value continues.¹⁴⁻¹⁶ We did a systematic review to clarify the accuracy of different electrocardiographic indexes, with emphasis on their ability to rule out left ventricular hypertrophy in patients with arterial hypertension.

METHODS

Identification of studies

We searched Medline and (Pre-)Medline (PubMed version) from 1966 to present (last update December 2005) and Embase (Ovid version) from 1980 to present (last update December 2005) to identify observational studies that evaluated the accuracy of

electrocardiographic indexes for the diagnosis of left ventricular hypertrophy and established the presence or absence of left ventricular hypertrophy with echocardiography. We restricted our search to papers published in English, German, Italian, Spanish, French, and Portuguese. The search strategies are available on request. Checks of the reference lists of relevant studies and contacts with experts in the field complemented the electronic searches.

Study selection

We included studies in asymptomatic patients with primary arterial hypertension in any type of healthcare setting. Studies included patients on antihypertensive treatment, patients with newly diagnosed hypertension being evaluated for treatment, and patients in whom treatment was withdrawn shortly before evaluation. We selected the studies in a two stage process. Two reviewers (DP and MB) independently assessed the abstracts of all retrieved studies. We ordered all papers considered to be potentially relevant by one reviewer and made the final decision by using a checklist to assess whether the criteria for inclusion had been met. We included all studies that assessed the electrocardiographic criteria in hypertensive adults against echocardiography (left ventricular mass indexed for body surface area) for whom sufficient data to allow the construction of the two by two table was available. We excluded studies that compared patients with known left ventricular hypertrophy with healthy controls (diagnostic case-control studies).^{17,18} We also excluded studies that used a reference standard calibrated according to heart mass/body height and studies that evaluated patients with concomitant left anterior fascicular block and left bundle branch block.

Data extraction

We extracted data in duplicate, including the number and characteristics of patients (mean age, distribution of sex and ethnic groups, mean body mass index, and smoking status), the healthcare setting (primary care versus secondary care), the prevalence of echocardiographically confirmed left ventricular hypertrophy, the electrocardiographic indexes evaluated, and the definition of the echocardiography threshold. We constructed two by two contingency tables for all electrocardiographic criteria reported in included articles. The data extraction form had been piloted for other diagnostic reviews and is described in detail elsewhere.¹⁹ We contacted first authors of eligible studies that reported insufficient data and asked them for additional information.

Assessment of study quality

We assessed the methodological quality of papers that met the eligibility criteria. We examined the methods of patient selection and data collection, completeness of descriptions of index and reference tests, completeness of blinding, and the likelihood of verification bias.^{17,18,20} We ranked studies as high quality if they

Definitions of six electrocardiographic indexes commonly used in diagnosis of left ventricular hypertrophy

- Sokolow-Lyon index⁹—sum of SV1+RV5 or V6>3.5 mV
- Cornell voltage index²²—men: RaVL+SV3>2.8 mV; women: RaVL+SV3>2.0 mV
- Cornell product²³—men: (SV3+RaVL)×QRS duration ≥2440 ms; women: (SV3+(RaVL+8 mV))×QRS duration>2440 ms
- Gubner¹²—RI+SIII≥25 mV
- Romhilt-Estes scores¹³—excessive amplitude: 3 points (largest R or S wave in limb leads ≥20 mV or S wave in V1 or V2 ≥30 mV or R wave in V5 or V6 ≥30 mV). ST-T segment pattern of LV strain: 3 points (ST-T segment vector shifted in direction opposite to mean QRS vector). Left atrial involvement: 3 points (terminal negativity of P wave in V1≥1 mm with duration ≥0.04 s). Left axis deviation: 2 points (left axis ≥−30° in frontal plane). Prolonged QRS duration: 1 point (≥0.09 s). Intrinsicoid deflection: 1 point (intrinsicoid deflection in V5 or V6≥0.05 s). Two thresholds in use: positive if ≥4 points or ≥5 points

described the setting (for example, family physicians referring patients to the clinic); collected data prospectively, with enrolment of consecutive patients and follow-up of all patients, including those who did not have echocardiography; and provided details on echocardiography and whether the assessor of the echocardiography was unaware of the electrocardiogram result or vice versa (blinding). We ranked studies as intermediate quality if they met four or five of the six criteria, as low quality if they met only one to three of the six criteria, and as very low quality if they met none of the criteria.

Statistical analysis

We added 0.5 to each cell of all two by two tables that included one or more zero cells. We calculated sensitivities, specificities, and likelihood ratios with their confidence intervals. As the electrocardiogram will mainly be used to rule out the diagnosis of left ventricular hypertrophy, we were particularly interested in the sensitivity and the likelihood ratio of a negative electrocardiogram result. The likelihood ratio of a negative test indicates how likely it is to find a negative result among people with left ventricular hypertrophy compared with those without.²¹ The negative likelihood ratio is calculated as (1−sensitivity)/specificity. It indicates to what extent the posterior odds of left ventricular hypertrophy would be reduced if the test was negative. If the prior odds is 1 and the negative likelihood ratio is 0.5, the posterior odds will be 1×0.5=0.5. The likelihood ratio of a positive test indicates how likely it is that a positive result will be found among people with left ventricular hypertrophy compared with those without; it is defined as sensitivity/(1−specificity).²¹ We summarised results by plotting sensitivities and specificities in the receiver operating curve space and

by calculating medians, ranges, and interquartile ranges.

RESULTS

Literature search

Our search identified 1761 citations. After exclusion of duplicates and examination of the abstracts we considered 142 as potentially eligible, and after scrutinising the full text articles we included 21 studies.^{w1-w21} Figure 1 summarises the process of assessing and selecting the studies. First authors provided additional information on nine studies.^{w1 w6 w10 w12 w16-w19 w21}

Study characteristics

The 21 studies included a total of 5608 (range 30-947) patients. Table 1 details the characteristics and methodological quality of the studies. Ten studies were done in primary care and 11 in secondary care. Three studies included only men; all others examined men and women. The median prevalence of left ventricular hypertrophy was 33% (interquartile range 23-41%) in primary care settings and 65% (37-81%) in secondary

care. Three studies met all six methodological criteria and were ranked as high quality. Another 11 studies met four or five criteria and were ranked as intermediate quality, whereas seven studies met two or three quality items and were considered of low quality. Table 1 lists the criteria met by different studies.

Electrocardiographic indexes

The 21 articles reported on 12 different electrocardiographic criteria. We analysed in detail the six most commonly used indexes, including the Sokolow-Lyon voltage index,⁹ the Cornell voltage and Cornell product indexes,^{10 11} the Gubner index,¹² and the Romhilt-Estes score with two different thresholds.¹³ The box shows definitions of these indexes.

Sensitivity, specificity, and likelihood ratios

Figure 2 shows the accuracy data for the six electrocardiographic indexes plotted in the receiver operating curve space. For all indexes, most studies are located in the bottom left corner of low sensitivity and high specificity. Table 2 shows, for each of the 21 studies,

Table 1 | Characteristics of studies of test accuracy of six commonly used electrocardiographic criteria for diagnosis of left ventricular hypertrophy

Study	Study characteristics				Patient characteristics				
	Setting	Echocardiographic criteria for LVH (mass index, g/m ²)	ECG criteria evaluated*	Methodological criteria met†	No of patients	Mean age (years)	Men (%)	Ethnicity	Prevalence of LVH (%)
Clementy, 1982 ^{w1}	Primary care	Men and women ≥120	A, B, E	3, 4	56	47	61	Caucasian	39
McLenachan, 1988 ^{w2}	Secondary care	Men ≥145; women ≥110	A, B, E	3, 4, 5	100	58	65	Caucasian	69
Calaca, 1990 ^{w3}	Secondary care	Men ≥134; women ≥110	C	3, 4	56	55	52	Caucasian	52
Otterstad, 1991 ^{w4}	Primary care	Men ≥124	A, C, E, H	2, 3	100	46	100	Caucasian	48
Padial, 1991 ^{w5}	Secondary care	Men ≥131; women ≥110	A, B, C	2, 3, 4, 5, 6	74	49	36	Caucasian	81
Vijan, 1991 ^{w6}	Secondary care	Men and women ≥115	A, E, I, K	1, 2, 3, 4, 5	75	54	79	Caucasian	65
Lee, 1992 ^{w7}	Primary care	Men ≥131; women ≥110	A, B, C, E	3, 4, 5, 6	270	54	69	Black (US), white (US)	23
Fragola, 1993 ^{w8}	Secondary care	Men ≥125; women ≥112	A, B, C, E, H, I	1, 3, 4, 5	200	51	62	Caucasian	35
Fragola, 1994 ^{w9}	Primary care	Men ≥125; women ≥112	A, C, E, H, I	1, 3, 4, 5, 6	100	50	62	Caucasian	26
Schillaci, 1994 ^{w10}	Primary care	Men ≥128; women ≥106	A, B, C, E, F, G, H, I	1, 2, 3, 4, 5	923	51	50	Caucasian	34
Tomiyama, 1994 ^{w11}	Primary care	Men ≥125	A, C, E	3, 4	77	–	100	Japanese	19
Crow, 1995 ^{w12}	Primary care	Men ≥134; women ≥110	A, C, E, D	1, 2, 3, 4, 5, 6	834	55	61	Black (US), white (US)	15
Casiglia, 1996 ^{w13}	Primary care	Men ≥134; women ≥110	A, C, E	1, 2, 3, 4, 5, 6	352	–	–	Caucasian	73
Kamide, 1996 ^{w14}	Secondary care	Men ≥134; women ≥110	A, E	1, 3, 4, 5, 6	48	70	–	Japanese	65
Domingos, 1998 ^{w15}	Secondary care	Men ≥120; women ≥98	A, B, C, E	2, 3, 4	30	57	40	White, Afro-Caribbean	83
Verdecchia, 2000 ^{w16}	Secondary care	Men ≥125; women ≥125	A, C, E, G, H	2, 3, 4, 5, 6	947	60	59	Caucasian	27
Chapman, 2001 ^{w17}	Secondary care	Men ≥134; women ≥110	A, C	1, 3, 4, 5	386	48	49	White, Afro-Caribbean, other (UK)	37
Sundström, 2001 ^{w18}	Primary care	Men ≥150	A, C, D, H	1, 3, 4, 6	212	70	100	Caucasian	41
Wong, 2003 ^{w19}	Secondary care	Men ≥134; women ≥110	A, C, D	1, 3, 4, 5	47	46	–	Caucasian	51
Martinez, 2003 ^{w20}	Primary care	Men ≥134; women ≥110	C	1, 3, 4, 6	250	49	47	Caucasian	32
Salles, 2005 ^{w21}	Secondary care	Men ≥116; women ≥104	A, C, D	1, 2, 3, 4, 5, 6	471	60	28	White, Afro-Caribbean	81

ECG=electrocardiogram; LVH=left ventricular hypertrophy.

*A=Sokolow-Lyon index; B=Gubner index; C=sex specific Cornell voltage; D=sex specific Cornell product; E=Romhilt-Estes score; F=Framingham criteria; G=Perugia score; H=left ventricular strain; I=left atrium enlargement; K=Sokolow-Lyon index and left ventricular strain.

†1=consecutive enrolment; 2=prospective design; 3=clear description of technique; 4=clear definition of cut-off levels; 5=blinded assessment of electrocardiogram; 6=blinded assessment of echocardiography.

Fig 1 | Flow chart of study selection process. MRI=magnetic resonance imaging

the number of true positives, false positives, false negatives, and true negatives, along with the corresponding sensitivities and specificities. The median sensitivity ranged from 10.5% (range 0-39%) for the Gubner index to 21% (4-52%) for the Sokolow-Lyon index. Median specificity ranged from 89% (53-100%) for the Sokolow-Lyon index to 99% (71-100%) for the Romhilt-Estes (five points) score.

Figures 3 and 4 show forest plots of the negative and positive likelihood ratios. The median negative likelihood ratio was similar across electrocardiographic indexes, ranging from 0.85 (range 0.34-1.03) for the Romhilt-Estes score (four points) to 0.91 (0.70-1.01) for the Gubner index. More variation existed in the positive likelihood ratio, which ranged from 1.90 (0.16-25.9) for the Sokolow-Lyon index to 5.90 (0.71-18.2) for the Romhilt-Estes score (four points). Using the median likelihood ratios from the Romhilt-Estes score (four points) in primary care, a negative electrocardiogram result would reduce the typical pre-test probability of 33% to 31%, whereas a positive electrocardiogram would increase it to 74%. In secondary care, the typical pre-test probability of 65% would be reduced to 63% or increased to 92%.

DISCUSSION

This systematic review of studies of the accuracy of diagnostic tests found that the accuracy of electrocardiographic indexes in the diagnosis of left ventricular hypertrophy is unsatisfactory. In particular, none of the more recent and more sophisticated indexes is clearly superior to the Sokolow-Lyon index, which was developed in 1949.⁹ Irrespective of the index

used, the electrocardiogram is a poor screening tool to exclude left ventricular hypertrophy in hypertensive patients in primary and secondary care settings. Of note, specificity was reasonably high in most studies, but because sensitivity was low the power to rule in left ventricular hypertrophy was also unsatisfactory, and the electrocardiogram cannot be considered a “SpPin” (specific, positive, in) test for the diagnosis of left ventricular hypertrophy.²¹

Strengths and limitations

We did a comprehensive literature search, selected studies according to pre-defined criteria, and appraised the methodological quality of studies. We acknowledge that we may have missed some studies, but their inclusion is unlikely to have changed our conclusions: empirical research suggests that unpublished studies of test accuracy are small and show lower diagnostic accuracy.²⁴ We excluded diagnostic case-control studies, which are known to overestimate accuracy,^{17 18} as well as studies that did not index ventricular mass for body surface area. We also excluded studies that evaluated patients with concomitant left anterior fascicular block and left bundle branch block, because these patients usually need further examinations and referral irrespective of left ventricular hypertrophy. We summarised the evidence by calculating medians, rather than combining data in meta-analysis. We believe that a formal meta-analysis would have added little in this situation. Similarly, we thought that further exploration of potential sources of heterogeneity was not warranted. The published data did not allow direct comparisons of test accuracy between the different indexes. More importantly, we did not identify any randomised comparisons of diagnostic and treatment strategies and assessed clinical end points.

Implications for clinical practice

Although many hypertensive patients have electrocardiographic testing for other reasons, electrocardiograms should not be done specifically to exclude left ventricular hypertrophy in patients with hypertension. A comprehensive assessment of cardiovascular risk is important to guide decisions on therapeutic interventions in these patients, and referral for echocardiography may be justified in some patients. Referral for specialist examinations and care is often based on high cardiovascular risk scores, but echocardiography may be more informative in hypertensive patients who, on the basis of age, sex, smoking history, and blood lipids, are at low or intermediate risk. In patients known to be at high risk, echocardiographic findings will often not affect clinical management, because interventions to reduce risk, such as example lipid lowering treatment, smoking cessation, and dietary modification, are already in place.

Recommendations from current guidelines differ. The 2003 European Society of Hypertension-European Society of Cardiology guidelines recommend echocardiography in patients in whom target organ damage is not discovered by routine

Table 2 | Results from test accuracy studies of electrocardiographic indexes in diagnosis of left ventricular hypertrophy: raw data from two by two tables, sensitivity, and specificity

Index/authors	True positives	False positives	False negatives	True negatives	Sensitivity (%)	Specificity (%)
Sokolow-Lyon						
Casiglia ^{w13}	30	14	228	80	12	85
Crow ^{w12}	10	19	118	687	8	97
Chapman ^{w17}	37	38	105	206	26	84
Clementy ^{w1}	8	0	14	34	36	100
Domingos ^{w15}	10	0	15	5	40	100
Fragola ^{w8}	20	14	49	117	29	89
Fragola ^{w9}	4	6	22	68	15	92
Kamide ^{w14}	11	5	20	12	35	71
Lee ^{w7}	9	30	52	179	15	86
McLenachan ^{w2}	36	2	33	29	52	94
Otterstad ^{w4}	14	5	34	47	29	90
Padial ^{w5}	8	2	52	12	13	86
Salles ^{w21}	75	13	308	75	20	85
Schillaci ^{w10}	64	69	248	542	21	89
Sundström ^{w18}	27	18	60	107	31	86
Tomiyama ^{w11}	6	29	9	33	40	53
Verdecchia ^{w16}	41	50	217	639	16	93
Vijan ^{w6}	8	0	41	26	16	100
Wong ^{w19}	1	6	23	17	4	74
Cornell voltage						
Calaca ^{w3}	12	2	17	25	41	93
Casiglia ^{w13}	10	0	67	51	13	100
Chapman ^{w17}	31	23	111	221	22	91
Crow ^{w12}	15	28	113	678	12	96
Domingos ^{w15}	3	0	22	5	12	100
Fragola ^{w8}	16	5	53	126	23	96
Fragola ^{w9}	2	5	24	69	8	93
Lee ^{w7}	6	6	55	203	10	97
Martinez ^{w20}	15	5	64	166	19	97
Otterstad ^{w1}	1	0	47	52	2	100
Padial ^{w5}	9	1	51	13	15	93
Salles ^{w21}	93	10	290	78	24	89
Schillaci ^{w10}	49	18	263	593	16	97
Sundström ^{w18}	14	14	73	111	16	89
Tomiyama ^{w11}	1	1	14	61	7	98
Verdecchia ^{w16}	52	62	206	627	20	91
Wong ^{w19}	2	0	22	23	8	100
Cornell product						
Crow ^{w12}	14	23	114	683	11	97
Salles ^{w21}	122	13	261	75	32	85
Sundström ^{w18}	24	21	63	104	28	83
Wong ^{w19}	2	0	22	23	8	100
Gubner						
Clementy ^{w1}	1	2	21	32	5	94
Domingos ^{w15}	7	1	18	4	28	80
Fragola ^{w8}	8	5	81	126	9	96
Lee ^{w7}	3	9	58	200	5	96
McLenachan ^{w2}	27	4	42	27	39	87
Schillaci ^{w10}	38	16	274	595	12	97
Verdecchia ^{w16}	33	28	225	661	13	96
Padial ^{w5}	0	0	60	14	0	100
Romhilt-Estes (threshold ≥4 points)						
Clementy ^{w1}	15	2	7	32	68	94
Fragola ^{w9}	2	8	24	66	8	89

McLenachan ^{w2}	35	2	34	29	50	94
Schillaci ^{w10}	55	6	254	608	18	99
Tomiyama ^{w11}	1	2	14	60	7	97
Vijan ^{w6}	10	1	39	25	20	96
Crow ^{w12}	20	17	108	689	16	98
Casiglia ^{w13}	41	14	217	80	16	85
Romhilt-Estes (threshold ≥ 5 points)						
Clementy ^{w1}	9	1	13	33	41	97
Domingos ^{w15}	3	0	22	5	12	100
Fragola ^{w8}	10	0	59	131	14	100
Fragola ^{w9}	1	1	25	73	4	99
Lee ^{w7}	4	6	57	203	7	97
Schillaci ^{w10}	46	3	263	611	15	99
Verdecchia ^{w16}	21	24	237	665	8	97
Kamide ^{w14}	5	5	26	12	16	71
Otterstad ^{w4}	0	0	48	52	0	100

See box for definitions of indexes.

electrocardiography.²⁵ The 2004 guidelines from the British Hypertension Society state that echocardiography is not required routinely but is valuable to confirm or refute the presence of left ventricular hypertrophy when the electrocardiogram shows high left ventricular voltage without T wave abnormalities.²⁶ In the United States, the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) recommends routine electrocardiography but makes no mention of echocardiography.²⁷

The evidence on the capacity of various antihypertensive agents to decrease left ventricular hypertrophy is limited. Several studies have shown a

possible advantage of angiotensin converting enzyme inhibitors and angiotensin II subtype 1 receptor antagonist based treatments in reducing left ventricular hypertrophy and preventing clinical events.²⁸ However, as most patients need several antihypertensive agents for optimal blood pressure control, the relative merits of each agent may be of lesser importance. In addition to antihypertensive drugs, preventing cardiovascular disease through modifications of other risk factors such as smoking cessation, lifestyle change, or lipid lowering treatment is the most promising approach.^{29,30} Indeed, moderate reductions in several risk factors might be more effective than major reductions in one.³¹

Fig 2 | Receiver operating curves of six commonly used electrocardiographic indexes for diagnosis of left ventricular hypertrophy. Each point represents one study

Future research

Further research is needed to identify cost effective diagnostic strategies in primary care settings, including randomised controlled trials that compare different diagnostic and treatment strategies and assess clinical end points. Such research could inform the development of algorithms to identify patients who should be referred for echocardiography. In the absence of accurate and inexpensive screening tests for left ventricular hypertrophy, research into new diagnostic technologies is also warranted. Of note, electrocardiographic left ventricular hypertrophy and echocardiographic left ventricular hypertrophy have been shown to predict mortality independently of each other and may therefore assess different aspects of the underlying pathology.⁵ Alternatively, they may measure the same condition with some imprecision.³² For example, in echocardiography, distinguishing physiological from pathological left ventricular hypertrophy can sometimes be difficult.⁵ Further studies are needed to better define the pathophysiological mechanisms and outcomes in patients with echocardiographically confirmed left ventricular hypertrophy but negative electrocardiograms. Similarly, more data are needed on patients with positive electrocardiographic tests but negative echocardiography.

Fig 3 | Forest plots of negative likelihood ratio from test accuracy studies of six electrocardiographic indexes in diagnosis of left ventricular hypertrophy. Points represent estimates of likelihood ratio; lines represent 95% confidence intervals

Electro-cardiographic index

Study

Sokolow-Lyon

Casiglia 1996^{w13}
 Chapman 2001^{w17}
 Clementy 1982^{w1}
 Crow 1995^{w12}
 Fragola 1993^{w8}
 Domingos 1998^{w15}
 Fragola 1994^{w9}
 Kamide 1996^{w14}
 Lee 1992^{w7}
 McLenachan 1988^{w2}
 Otterstad 1991^{w4}
 Padial 1991^{w5}
 Salles 2005^{w21}
 Schillaci 1994^{w10}
 Sundström 2001^{w18}
 Tomiyama 1994^{w11}
 Verdecchia 2000^{w16}
 Vijan 1991^{w6}
 Wong 2003^{w19}

Positive likelihood ratio (95% CI)

0.78 (0.43 to 1.41)
 1.67 (1.12 to 2.50)
 25.9 (1.57 to 426)
 2.90 (1.38 to 6.10)
 4.85 (0.33 to 71.7)
 2.71 (1.46 to 5.03)
 1.90 (0.58 to 6.20)
 1.21 (0.50 to 2.90)
 1.03 (0.52 to 2.05)
 8.09 (2.08 to 31.5)
 3.03 (1.18 to 7.79)
 0.93 (0.22 to 3.92)
 1.33 (0.77 to 2.28)
 1.82 (1.33 to 2.48)
 2.16 (1.27 to 3.66)
 0.86 (0.44 to 1.68)
 2.19 (1.49 to 3.23)
 9.18 (0.55 to 153)
 0.16 (0.02 to 1.23)

Cornell voltage

Otterstad 1991^{w4}
 Tomiyama 1994^{w11}
 Fragola 1994^{w9}
 Lee 1992^{w7}
 Padial 1991^{w5}
 Fragola 1993^{w8}
 Chapman 2001^{w17}
 Schillaci 1994^{w10}
 Verdecchia 2000^{w16}
 Crow 1995^{w12}
 Martinez 2003^{w20}
 Sundström 2001^{w18}
 Wong 2003^{w19}
 Salles 2005^{w21}
 Domingos 1998^{w15}
 Calaca 1990^{w3}

3.24 (0.14 to 77.8)
 4.13 (0.27 to 62.4)
 1.14 (0.24 to 5.51)
 3.43 (1.15 to 10.2)
 2.10 (0.29 to 15.3)
 6.08 (2.32 to 15.9)
 2.32 (1.41 to 3.81)
 5.33 (3.16 to 8.99)
 2.24 (1.59 to 3.15)
 2.95 (1.62 to 5.37)
 6.49 (2.45 to 17.2)
 1.44 (0.72 to 2.86)
 4.80 (0.24 to 94.9)
 2.14 (1.16 to 3.93)
 1.62 (0.10 to 27.3)
 5.59 (1.37 to 22.7)

Cornell product

Crow 1995^{w12}
 Sundström 2001^{w18}
 Wong 2003^{w6}
 Salles 2005^{w21}

3.36 (1.78 to 6.35)
 1.64 (0.98 to 2.76)
 4.80 (0.24 to 94.9)
 2.16 (1.28 to 3.64)

Gubner

Clementy 1982^{w1}
 Fragola 1993^{w8}
 Lee 1992^{w7}
 McLenachan 1988^{w2}
 Schillaci 1994^{w10}
 Verdecchia 2000^{w16}
 Domingos 1998^{w15}

0.77 (0.07 to 8.02)
 2.36 (0.80 to 6.97)
 1.14 (0.32 to 4.09)
 3.03 (1.16 to 7.93)
 4.65 (2.64 to 8.21)
 3.15 (1.94 to 5.10)
 1.40 (0.22 to 9.01)

Romhilt-Estes (four points)

Clementy 1982^{w1}
 Fragola 1994^{w9}
 McLenachan 1988^{w2}
 Schillaci 1994^{w10}
 Tomiyama 1994^{w11}
 Vijan 1991^{w6}
 Crow 1995^{w12}
 Casiglia 1996^{w13}

11.6 (2.93 to 45.8)
 0.71 (0.16 to 3.14)
 7.86 (2.02 to 30.6)
 18.2 (7.93 to 41.8)
 2.07 (0.20 to 21.3)
 5.31 (0.72 to 39.2)
 6.49 (3.50 to 12.0)
 1.07 (0.61 to 1.87)

Romhilt-Estes (five points)

Clementy 1982^{w1}
 Fragola 1993^{w8}
 Fragola 1994^{w9}
 Lee 1992^{w7}
 Schillaci 1994^{w10}
 Verdecchia 2000^{w16}
 Kamide 1996^{w14}
 Domingos 1998^{w15}

13.9 (1.89 to 102)
 39.6 (2.36 to 665)
 2.85 (0.18 to 43.9)
 2.28 (0.67 to 7.83)
 30.5 (9.55 to 97.2)
 2.34 (1.32 to 4.12)
 0.55 (0.18 to 1.63)
 1.62 (0.10 to 27.4)

Fig 4 | Forest plots of positive likelihood ratio from test accuracy studies of six electrocardiographic indexes in diagnosis of left ventricular hypertrophy. Points represent estimates of likelihood ratio; lines represent 95% confidence intervals

WHAT IS ALREADY KNOWN ON THIS TOPIC

Left ventricular hypertrophy leads to a fivefold to 10-fold increase in cardiovascular risk in hypertensive patients

Several indexes calculated from standard 12 lead electrocardiograms are used in the diagnostic work-up of patients with hypertension

WHAT THIS PAPER ADDS

The accuracy of the more commonly used electrocardiographic criteria for ruling out left ventricular hypertrophy is unsatisfactory in both primary and secondary care.

Echocardiography is needed for a comprehensive assessment of cardiovascular risk in hypertensive patients

Conclusions

The power of some of the more commonly used electrocardiographic criteria to rule out the diagnosis of left ventricular hypertrophy in patients with hypertension is poor. Further research is needed to assess the cost effectiveness of different diagnostic and treatment strategies and to develop alternative diagnostic technologies for assessment of left ventricular hypertrophy in primary care.

We thank Marc Gertsch, Richard S Crow, Benedict Martina, Fritz Grossenbacher, and Heiner C Bucher for valuable input and for commenting on an earlier draft.

Contributors: DP, ME, PJ, and MB initiated the study and wrote the protocol. DP and MB did the searches, screened the literature, and extracted the data. LMB did the analysis, supervised the work, and wrote a first draft, which was subsequently revised by ME. All authors participated in interpreting the data and critically revising the manuscript for important intellectual content. ME is the guarantor.

Funding: Krankenfürsorgestiftung der Gesellschaft für das Gute und Gemeinnützige (GGG), Basel, Switzerland, Swiss National Science Foundation (grant 3233BO-103182 and 3200BO-103183).

Competing interests: None declared.

Ethical approval: Not needed.

Provenance and peer review: Non-commissioned; externally peer reviewed.

- Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram: prevalence, incidence, and mortality in the Framingham study. *Ann Intern Med* 1969;71:89-105.
- Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease: the Framingham study. *Ann Intern Med* 1970;72:813-22.
- Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. *J Am Coll Cardiol* 1998;32:1454-9.
- Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic value of a new electrocardiographic method for diagnosis of left ventricular hypertrophy in essential hypertension. *J Am Coll Cardiol* 1998;31:383-90.
- Sundström J, Lind L, Amlöv J, Zethelius B, Andrén B, Lithell HO. Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. *Circulation* 2001;103:2346-51.
- Dunn FG, McLenachan J, Isles CG, Brown I, Dargie HJ, Lever AF, et al. Left ventricular hypertrophy and mortality in hypertension: an analysis of data from the Glasgow Blood Pressure Clinic. *J Hypertens* 1990;8:775-82.
- Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial—lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet* 2003;361:1149-58.
- Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. *BMJ* 2004;328:634-40.
- Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. *Am Heart J* 1949;37:161-86.
- Casale PN, Devereux RB, Kligfield P, Eisenberg RR, Miller DH, Chaudhary BS, et al. Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. *J Am Coll Cardiol* 1985;6:572-80.
- Norman JE Jr, Levy D. Adjustment of ECG left ventricular hypertrophy criteria for body mass index and age improves classification accuracy: the effects of hypertension and obesity. *J Electrocardiol* 1996;29(suppl):241-7.
- Gubner R, Ungerleider HE. Electrocardiographic criteria of left ventricular hypertrophy. *Arch Intern Med* 1943;72:196-206.
- Romhilt DW, Estes EH Jr. A point-score system for the ECG diagnosis of left ventricular hypertrophy. *Am Heart J* 1968;75:752-8.
- Schillaci G, Verdecchia P, Pedr S, Porcellati C. Electrocardiography for left ventricular hypertrophy in hypertension: time for re-evaluation? *G Ital Cardiol* 1998;28:706-13.
- Verdecchia P, Dovellini EV, Gorini M, Gozzelino G, Lucci D, Millettich A, et al. Comparison of electrocardiographic criteria for diagnosis of left ventricular hypertrophy in hypertension: the MAVI study. *Ital Heart J* 2000;1:207-15.
- Conway D, Lip GY. The ECG and left ventricular hypertrophy in primary care hypertensives. *J Hum Hypertens* 2001;15:215-7.
- Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, van der Meulen JH, et al. Empirical evidence of design-related bias in studies of diagnostic tests. *JAMA* 1999;282:1061-6.
- Whiting P, Rutjes AW, Reitsma JB, Glas AS, Bossuyt PM, Kleijnen J. Sources of variation and bias in studies of diagnostic accuracy: a systematic review. *Ann Intern Med* 2004;140:189-202.
- Horvath AR, Pewsner D. Systematic reviews in laboratory medicine: principles, processes and practical considerations. *Clin Chem Acta* 2004;342:23-39.
- Jaeschke R, Guyatt G, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid? *JAMA* 1994;271:389-91.
- Pewsner D, Battaglia M, Minder C, Marx A, Bucher HC, Egger M. Ruling a diagnosis in or out with "SpIn" and "SnOut": a note of caution. *BMJ* 2004;329:209-13.
- Casale PN, Devereux RB, Alonso DR, Campo E, Kligfield P. Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. *Circulation* 1987;75:565-72.
- Molloy TJ, Okin PM, Devereux RB, Kligfield P. Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. *J Am Coll Cardiol* 1992;20:1180-6.
- Song F, Khan KS, Dinnes J, Sutton AJ. Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. *Int J Epidemiol* 2002;31:88-95.
- European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. *J Hypertens* 2003;21:1011-53.
- Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004 -BHS IV. *J Hum Hypertens* 2004;18:139-85.
- Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA* 2003;289:2560-72.
- Reims HM, Oparil S, Kjeldsen SE, Devereux RB, Julius S, Brady WE, et al. Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study. *Blood Press* 2004;13:376-84.
- Appel LJ, Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elmer PJ, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. *JAMA* 2003;289:2083-93.
- Svetkey LP, Erlinger TP, Vollmer WM, Feldstein A, Cooper LS, Appel LJ, et al. Effect of lifestyle modifications on blood pressure by race, sex, hypertension status, and age. *J Hum Hypertens* 2005;19:21-31.
- Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. *Lancet* 2005;365:434-41.
- Phillips AN, Smith GD. Bias in relative odds estimation owing to imprecise measurement of correlated exposures. *Stat Med* 1992;11:953-61.

Accepted: 11 July 2007